• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Vivani Medical Inc.

    4/29/25 8:03:53 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VANI alert in real time by email
    DEFA14A 1 g084790_defa14a.htm DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 14A 

    Proxy Statement Pursuant to Section 14(a) of the Securities
    Exchange Act of 1934

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to §240.14a-12

     

    VIVANI MEDICAL, INC. 

    (Name of Registrant as Specified In Its Charter) 

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required.
    ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
      (1) Title of each class of securities to which transaction applies:  
      (2) Aggregate number of securities to which transaction applies:  
      (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined);  
      (4) Proposed maximum aggregate value of transaction:  
      (5) Total fee paid:
    ☐ Fee paid previously with preliminary materials.
    ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
      (1) Amount Previously Paid: 
      (2) Form, Schedule or Registration Statement No.: 
      (3) Filing Party: 
      (4) Date Filed: 

     

     

     

     

     

     

     

     

     

     

     

    Get the next $VANI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VANI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VANI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vivani Medical Appoints Anthony Baldor as Chief Financial Officer

      ALAMEDA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of Anthony Baldor as Chief Financial Officer. Baldor succeeds Brigid A. Makes, who has decided to retire from Vivani to focus on her board appointments and personal projects after a distinguished career and significant contributions to the Company. Baldor brings more than 20 years of financial management experience in the biotechnology sector, with a proven record in fundraising, business development and corporate strategy. Prior to joining Vivani,

      6/11/25 8:00:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical to Present at the 2025 BIO International Convention

      ALAMEDA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) (the "Company" or "Vivani"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the 2025 BIO International Convention, taking place from June 16-19, 2025 in Boston, Massachusetts. Details around Dr. Mendelsohn's presentation are as follows: Date:Wednesday, June 18, 2025Time:9:00 am, Eastern TimeLocation: Boston Convention & Exhibition Center, Room 153A   Dr. Mendelsohn will highlight Vivani's innovative, miniature drug implants, powered by its

      6/10/25 8:30:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders

      Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion® Visual Cortical Prosthesis System to provide meaningful visual perception to people who are blind Cortigent is developing the Stroke Recovery System to improve the recovery of arm and hand movement in people who have suffered paralysis due to stroke Spin-off will allow Vivani to focus on its continued development of miniature, ultra long-acting GLP-1 implants for chronic weight management and type 2 diabetes with annual or bi-annual dosing ALAMEDA, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Viv

      5/29/25 8:30:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    SEC Filings

    See more
    • Vivani Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      6/25/25 4:28:57 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      6/17/25 6:16:00 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Vivani Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      6/11/25 8:45:22 AM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Williams Gregg bought $12,867 worth of shares (12,740 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      5/16/25 8:11:15 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Williams Gregg bought $1,124 worth of shares (1,113 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      4/28/25 7:59:38 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Williams Gregg bought $1,830 worth of shares (1,812 units at $1.01) (SEC Form 4)

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      4/23/25 8:41:13 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mendelsohn Aaron

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      6/26/25 8:33:36 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Williams Gregg

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      6/26/25 7:28:12 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Baker Wilford Dean

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      6/26/25 7:27:00 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $VANI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)

      SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

      5/1/23 8:42:07 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by Vivani Medical Inc.

      SC 13D - Vivani Medical, Inc. (0001266806) (Subject)

      4/25/23 5:28:48 PM ET
      $VANI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care